SCHEMBL288542

SCHEMBL288542

O=S(=O)(Cl)c1csc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CYP2A6 P11509 3/20 0.46
PDPK1 O15530 1/20 0.44
MAPT P10636 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
PKM P14618 2/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29469856 1.00 CA1 (0.47) CA1CA2CYP2A6PDPK1MAPT
SCHEMBL7491058 0.80 CYP2A6 (0.46) CA1CA2CYP2A6PDPK1MAPT
SCHEMBL14089195 0.80 CYP2A6 (0.46) CA1CA2CYP2A6PDPK1MAPT
SCHEMBL2703947 0.80 CYP2A6 (0.47) CA1CA2CYP2A6PDPK1MAPT
SCHEMBL31287752 0.80 CA2 (0.51) CA1CA2CYP2A6PDPK1MAPT
SCHEMBL1034849 0.80 CA2 (0.51) CA1CA2CYP2A6PDPK1MAPT
SCHEMBL6628789 0.78 CYP2A6 (0.44) CA1CA2CYP2A6PDPK1MAPT
Hydrochloric Acid SCHEMBL27734063 0.78 CYP2A6 (0.46) CA1CA2CYP2A6PDPK1MAPT
Potassium Ion SCHEMBL4239766 0.78 CYP2A6 (0.44) CA1CA2CYP2A6PDPK1MAPT
SCHEMBL6766434 0.78 CYP2A6 (0.46) CA1CA2CYP2A6PDPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739671-A1 NEW COMPOUNDS Aston University (GB) 2026-05-13 EP disclosed
EP-4661966-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF Type6 Therapeutics, Inc. (US) 2025-12-17 EP disclosed
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof Maxymune Therapeutics, Inc. (US) 2025-09-30 US disclosed
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use Oxford Drug Design Limited (GB) 2025-03-11 US disclosed
WO-2025008627-A1 NEW COMPOUNDS ASTON UNIVERSITY (GB) 2025-01-09 WO disclosed
CN-118852135-A N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-10-29 CN disclosed
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-22 US disclosed
WO-2024167848-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF TYPE6 THERAPEUTICS, INC. (US) 2024-08-15 WO disclosed
EP-0687253-A1 NEW 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME Roche Diagnostics GmbH (DE) 1995-12-20 EP disclosed
WO-1994020467-A1 NEW 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME BOEHRINGER MANNHEIM GMBH (DE) 1994-09-15 WO disclosed
EP-0340010-B1 Heterocyclic nitromethane derivatives ICI PLC (GB) 1994-08-24 EP disclosed
US-5102905-A For treating side effects of diabetes and galactosemia IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-04-07 US disclosed
EP-0340010-A2 Heterocyclic nitromethane derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-11-02 EP disclosed
US-4725604-A ADMINISTERING 2-(SUBSTITUTED-ETHYLTHIO) INDOLES OR BENZOTHIOPHENES MCNEILAB, INC. (US) 1988-02-16 US disclosed
US-4584302-A ADMINISTERING INDOLE AND BENZOTHIPOPHENE COMPOUNDS HAVING PENDANT PYRROLIDINYLIDENE AMINO OR PIPERIDINYIDENEAMINO GROUPS MCNEILAB, INC. (US) 1986-04-22 US disclosed
EP-0045196-B1 HERBICIDAL BENZOTHIOPHENE AND BENZOFURAN SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-11-13 EP disclosed
US-4391627-A Herbicidal benzothiophene and benzofuran sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1983-07-05 US disclosed
EP-0045196-A2 Herbicidal benzothiophene and benzofuran sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use AARS1, ASNS, GARS1 CA1 4200/4885CA2 2761/4885CYP2A6 562/4885
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 CA1 4697/4885CA2 3741/4885CYP2A6 3264/4885
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A CA1 1714/4885CA2 2865/4885CYP2A6 170/4885
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof SLC43A1, SLC7A1, SLC1A5 CA1 4697/4885CA2 3741/4885CYP2A6 3264/4885
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 CA1 4697/4885CA2 3741/4885CYP2A6 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.